UY37160A - COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 - Google Patents

COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6

Info

Publication number
UY37160A
UY37160A UY0001037160A UY37160A UY37160A UY 37160 A UY37160 A UY 37160A UY 0001037160 A UY0001037160 A UY 0001037160A UY 37160 A UY37160 A UY 37160A UY 37160 A UY37160 A UY 37160A
Authority
UY
Uruguay
Prior art keywords
avß6
integrine
pirrolidine
antagonist activity
compounds derived
Prior art date
Application number
UY0001037160A
Other languages
English (en)
Inventor
Mary Redmond Joanna
Howard James Campbellcrawford Matthew
Andrew Anderson Niall
Alexandrou Procopiou Panayiotis
Seble Lemma
Martin Pritchard John
Paul Hancock Ashley
Leslie Sollis Steven
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY37160A publication Critical patent/UY37160A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a compuestos de la fórmula (I): en donde R1, R2y R3, son tal como se los define en la descripción y en las reivindicaciones, o sus sales farmacéuticamente aceptables, que tienen una actividad antagonista de la integrina avß6, a composiciones farmacéuticas que incluyen dicho compuesto o una sal del mismo, y al uso de dicho compuesto o una sal del mismo en terapia, incluso en el tratamiento de una enfermedad o afección para la cual está indicado un antagonista de la integrina avß6, y en particular, en el tratamiento de fibrosis pulmonar idiopática.
UY0001037160A 2016-03-21 2017-03-20 COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 UY37160A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1604681.5A GB201604681D0 (en) 2016-03-21 2016-03-21 Chemical Compounds

Publications (1)

Publication Number Publication Date
UY37160A true UY37160A (es) 2017-09-29

Family

ID=55968580

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037160A UY37160A (es) 2016-03-21 2017-03-20 COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6

Country Status (14)

Country Link
US (1) US20210206758A1 (es)
EP (1) EP3433255A1 (es)
JP (1) JP2019509305A (es)
KR (1) KR20180128404A (es)
CN (1) CN108779114A (es)
AR (1) AR107927A1 (es)
AU (1) AU2017237362A1 (es)
BR (1) BR112018069302A2 (es)
CA (1) CA3018014A1 (es)
GB (1) GB201604681D0 (es)
RU (1) RU2018136888A (es)
TW (1) TW201808949A (es)
UY (1) UY37160A (es)
WO (1) WO2017162572A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
AU2018229275B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2018160522A1 (en) 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CA3093225A1 (en) 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
UY38352A (es) * 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
TW202035400A (zh) 2018-08-29 2020-10-01 美商莫菲克醫療股份有限公司 抑制αvβ6整合素
WO2020047207A1 (en) * 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CN113620938A (zh) * 2020-05-07 2021-11-09 北京康派森医药科技有限公司 一种恩格列净异构体杂质的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229910A4 (en) * 1999-10-04 2003-10-01 Merck & Co Inc integrin
JP2003513974A (ja) * 1999-11-08 2003-04-15 メルク エンド カムパニー インコーポレーテッド イミダゾリジノン系αｖ−インテグリン拮抗薬の製造方法および製造用中間体
US6921767B2 (en) 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
BRPI0308585B8 (pt) 2002-03-13 2021-05-25 Biogen Idec Inc anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
CA2823955A1 (en) 2011-01-19 2012-07-26 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
US20150178760A1 (en) 2012-07-24 2015-06-25 Empire Technology Development Llc Methods for valuation of recycling credits
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound

Also Published As

Publication number Publication date
CA3018014A1 (en) 2017-09-28
GB201604681D0 (en) 2016-05-04
US20210206758A1 (en) 2021-07-08
EP3433255A1 (en) 2019-01-30
WO2017162572A1 (en) 2017-09-28
RU2018136888A (ru) 2020-04-22
BR112018069302A2 (pt) 2019-01-22
KR20180128404A (ko) 2018-12-03
JP2019509305A (ja) 2019-04-04
CN108779114A (zh) 2018-11-09
AU2017237362A1 (en) 2018-08-09
AR107927A1 (es) 2018-06-28
TW201808949A (zh) 2018-03-16

Similar Documents

Publication Publication Date Title
UY37160A (es) COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CL2018002803A1 (es) Antagonistas de c5ar solubles
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
ECSP17073965A (es) Derivados de ciclohexano sustituido con amido
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
DOP2015000216A (es) Inhibidores de bromodominios tetraciclicos
SV2018005680A (es) Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
UY37205A (es) Inhibidores de bromodominios
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
EA201692003A1 (ru) Макроциклические производные пиримидина
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CR20140516A (es) Compuestos de pirazol sustituidos como antagonistas de lpar
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201890532A1 (ru) Новые аннелированные бензамиды
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
EA201692298A1 (ru) Производные карбоксамидов

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201204